Alnylam Pharma Shares Surge After Lift In FY25 Product Revenue View, Despite Wider Q2 Loss

(RTTNews) - Shares of Alnylam Pharmaceuticals, Inc. (ALNY) were surging around 18% in the mid-day trading on the Nasdaq, after the RNAi therapeutics company raised its fiscal 2025 outlook after reporting higher second-quarter revenues. Meanwhile, the company recorded wider loss in its latest quarter.

For fiscal 2025, the company now expects total net product revenues between $2.65 billion and $2.80 billion, higher than previous estimate of $2.05 billion and $2.25 billion.

The company said the revision of 27% growth in outlook at the mid point reflects the strong progress during the first half of 2025 and the firm's confidence in the overall business for the rest of the year.

The revised outlook reflects an year-over-year growth of 61% to 70% from last year, compared to previously expected growth of 25% to 37%.

Further, Alnylam announced that it will present results from the KARDIA-3 Phase 2 trial of zilebesiran in patients with hypertension during a Hot Line Session at the European Society of Cardiology (ESC) Congress in Madrid, Spain on August 30.

In the second quarter, the company reported net loss of $66.28 million, compared to prior year's loss of $16.89 million. Loss per share was $0.51, compared to loss of $0.13 last year.

Adjusted earnings were $95.48 million or $0.32 per share for the period, compared to $0.56 last year. Analysts projected $0.15 per share.

Revenue grew 17% to $773.69 million in the quarter from $659.83 million in the same period last year.

On the Nasdaq, Alnylam Pharma shares were trading at $400.52, up 17.87%.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.